Abivax (NASDAQ:ABVX) Price Target Raised to $148.00 at Barclays

Abivax (NASDAQ:ABVX) had its target price raised by Barclays from $142.00 to $148.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other equities analysts have also recently weighed in on ABVX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a report on Wednesday, January 21st. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Jefferies Financial Group began coverage on Abivax in a research report on Monday, March 16th. They issued a “buy” rating and a $160.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $175.00 target price on shares of Abivax in a research report on Thursday, December 18th. Finally, Truist Financial set a $140.00 price target on shares of Abivax in a research note on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $137.15.

Abivax Stock Down 4.5%

ABVX opened at $110.17 on Tuesday. Abivax has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The company has a fifty day moving average of $119.11 and a two-hundred day moving average of $110.93. The stock has a market capitalization of $8.72 billion, a price-to-earnings ratio of -20.52 and a beta of 1.00.

Abivax (NASDAQ:ABVX) last posted its earnings results on Monday, March 23rd. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.24) by $1.00. The firm had revenue of $1.45 million for the quarter, compared to analysts’ expectations of $1.80 million. On average, research analysts expect that Abivax will post -2.83 earnings per share for the current year.

Hedge Funds Weigh In On Abivax

A number of institutional investors and hedge funds have recently bought and sold shares of ABVX. EverSource Wealth Advisors LLC raised its holdings in Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Abivax in the third quarter valued at approximately $36,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Abivax in the fourth quarter valued at approximately $61,000. Finally, WPG Advisers LLC grew its position in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Abivax

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Barclays raised its price target to $148 and kept an “overweight” rating, highlighting analyst confidence in upside from upcoming catalysts. Barclays raises price target
• Positive Sentiment: Abivax reported quarterly results that materially beat EPS expectations (reported loss per share smaller than forecast), which reduces near-term execution risk relative to estimates. Revenue modestly missed. Quarterly results press release
• Neutral Sentiment: Abivax announced appointments of three key executives — a governance/operational update that may help execution but is not an immediate revenue catalyst. Abivax appoints three key executives
• Neutral Sentiment: Company filed full-year 2025 results and business updates; investors should review the release for detail on cash position, pipeline timing and guidance. Full-year 2025 results and updates
• Neutral Sentiment: Multiple short-interest reports show a large increase but the published figures read as 0 shares / NaN changes and a 0.0 days-to-cover — the data appears unreliable, so don’t read meaningful short-squeeze signals from these filings.
• Negative Sentiment: Management publicly downplayed urgency for M&A, saying the company prefers to wait for a key trial data readout in Q2 and is preparing for a capital raise; that reduces takeover speculation and raises dilution/funding concerns in the near term. CNBC: Abivax in no rush for a deal Benzinga: CEO downplays sale talk

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.